In the striatum, adenosine A 2A and dopamine D 2 receptors exert reciprocal antagonistic interactions that modulate the function of GABAergic enkephalinergic neurons. We have previously shown that stimulation of adenosine A 1 receptors allows the stimulation of A 2A receptors to overcome a tonic inhibitory effect of D 2 receptors and induce striatal expression of c-fos. In the present work, by studying co-localization of c-Fos immunoreactivity and preproenkephalin and preprodynorphin transcripts, we show that co-administration of the A 1 receptor agonist CPA and the A 2A receptor agonist CGS 21680 increases the striatal expression of c-fos in GABAergic enkephalinergic but not in GABAergic dynorphinergic neurons. Co-administration of CPA and CGS 21680 also induced a significant increase in the striatal expression of preproenkephalin. The results underscore the role of adenosine in the activation of gene expression in the GABAergic enkephalinergic neuron.
INTRODUCTION
Adenosine and dopamine modulate the activity of the striatal g-aminobutyric acid (GABA)ergic efferent neurons, which constitute more than 90% of the neuronal population in the striatum. Striatal GABAergic efferent neurons can be classified into two major classes according to their peptide expression. GABAergic enkephalinergic neurons express dopamine and adenosine receptors predominantly of the D 2 and A 2A subtype, respectively, while GABAergic dynorphinergic neurons predominantly express dopamine D 1 and adenosine A 1 receptors (for reviews, see Ferré et al, 1997; Gerfen, 2004) .
Studies on the expression of immediate-early genes, such as c-fos, and of the expression of the peptide genes, such as preproenkephalin and preprodynorphin (precursors of enkephalin and dynorphin, respectively), have consistently shown a differential effect of dopamine in the two striatal GABAergic efferent neurons (Gerfen, 2004) . This is due to the segregation of D 1 and D 2 receptors, whose activation stimulates and inhibits the function of GABAergic dynorphinergic and GABAergic enkephalinergic neurons, respectively (Gerfen, 2000) . A 2A and D 2 receptors exert reciprocal antagonistic interactions that modulate the function of GABAergic enkephalinergic neurons (Ferré et al, 1993 (Ferré et al, , 1997 Agnati et al, 2003) and recent studies have demonstrated the ability of A 2A and D 2 receptors to heteromerize Kamiya et al, 2003; Ciruela et al, 2004; Woods and Ferré, 2005) . A 2A and D 2 receptors are prototypical G s -and G i -coupled receptors, respectively, which play opposite effects on adenylyl-cyclase (Kull et al, 1999; Hillion et al, 2002; Lee et al, 2002) . Stimulation of A 2A receptors can potentially stimulate striatal adenylyl-cyclase, with the consequent activation of the cAMP-PKA signaling pathway and the induction of the expression of different genes, such as c-fos and preproenkephalin (Agnati et al, 2003; Ferré et al, 2003 Ferré et al, , 2004 . However, under normal conditions, the ability of A 2A receptors to activate the cAMP-PKA signaling pathway is restrained by the tonic inhibitory effect of D 2 receptors, which potently inhibit A 2A -receptor mediated adenylyl-cyclase activation (Agnati et al, 2003; Ferré et al, 2003 Ferré et al, , 2004 . We have shown that activation of adenosine A 1 receptors allows A 2A receptors to overcome the inhibitory effect of D 2 receptors and induce striatal expression of c-fos (Karcz-Kubicha et al, 2003) . However, it remained to be demonstrated if this increase in c-fos expression takes place in GABAergic enkephalinergic neurons.
In the present work, we used a combination of immunohistochemistry, to detect c-Fos (a cellular marker for neuronal activation), and in situ hybridization to determine the phenotype (enkephalinergic or dynorphinergic) of striatal neurons activated by co-administration of A 1 and A 2A receptor agonists.
METHODS

Subjects and Drugs
Male Sprague-Dawley rats (Charles River Laboratory, Wilmington, MA, USA), weighing 300-350 g were used in all experiments. Animals were maintained in accordance with guidelines of the Institutional Care and Use Committee of the Intramural Research Program, National Institute on Drug Abuse, NIH. The A 1 receptor agonist N 6 -cyclopentyladenosine (CPA) and the adenosine A 2A receptor agonist 2-p-(2-carboxyethyl)phenethylamino-5 0 -N-ethylcarboxamidoadenosine (CGS 21680) were purchased from Sigma Chemical Company (St Louis, MO, USA). Both drugs were dissolved in sterile saline and administered intraperitoneally (i.p.) in a volume of 2 ml/kg of body weight.
In Situ Hybridization and Immunocytochemistry
At 2 h following the administration of drugs, rats were anesthetized with Equithesin (NIDA Pharmacy, Baltimore, MD, USA) and perfused transcardially with a solution of 4% (W/V) paraformaldehyde in 0.1 M phosphate buffer (PB), pH 7.3. The brains were postfixed for 2 h, immersed in 20% sucrose in PB overnight and frozen in powdered dry ice. Sections were cut at 30 mm thickness and stored frozen in cryoprotectant (Morales et al, 1998) . Phenotypic characterization of enkephalinergic and dynorphinergic neurons was carried out by in situ hybridization as previously described (Backman et al, 2001) . Sections were washed three times in PB, incubated for 10 min in PB containing 0.5% Triton X-100, rinsed 2 Â 5 min with PB, treated with 0.2 N HCl for 10 min, rinsed 2 Â 5 min with PB, and then acetylated in 0.25% acetic anhydride in 0.1 M triethanolamine, pH 8.0 for 10 min. Sections were rinsed 2 Â 5 min with PB, postfixed with 4% paraformaldehyde for 10 min, and after a final rinse with PB were hybridized at 551C for 16 h in hybridization buffer (50% formamide; 10% dextran sulfate; 5 Â Denhardt's solution; 0.62 M NaCl; 50 mM DTT; 10 mM EDTA; 20 mM PIPES, pH 6.8; 0.2% SDS; 250 mg/ml ssDNA; 250 mg/ml tRNA) containing 10 7 cpm/ml of each P-labeled specific activity 3000 Ci/mM, Perkin-Elmer, Boston, MA), 1.5 mmol each of rATP, rCTP, and rGTP in a volume of 20 ml. Transcription reactions were carried out at 371C for 120 min with the addition of 20 U of RNA polymerase at 60 min. Complementary RNA probes were purified by gel filtration column chromatography (Roche, Indianapolis, IN).
Sections were rinsed in 2 Â SSC before incubation with RNase A at 4 mg/ml at 371C for 1 h, washed with 1 Â SSC, 50% formamide at 551C for 1 h, and with 0.1 Â SSC at 681C for 1 h. After this last SSC wash, sections were rinsed with PB buffer and then incubated in 4% bovine serum albumin supplemented with 0.3% Triton-X-100 in PB for 1 h followed by incubation with a polyclonal anti c-Fos antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:1000 dilution for 24 h at 41C. Sections were processed with an ABC kit (Vector) and peroxidase activity was revealed with 0.003% H 2 O 2 and 0.05% 3,3-diaminobenzidine-4 HCl. Brain sections were mounted on coated slides, dehydrated in ethanol, treated with Histoclear, rinsed in 100% ethanol and exposed to BAS-MS 2025 imaging plates (Fujifilm, Stamford, CT) for multiple exposure times to determine the linear range of detection and produce clear images using a BAS-5000 imaging plate scanner (Fujifilm, Stamford, CT). Thereafter, sections were dipped in nuclear track emulsion and exposed for several weeks prior to development. Two sets of experiments were performed and analyzed independently. The first set included a group treated with saline (control) and a group treated with CGS 21680 (0.5 mg/kg, i.p.) plus CPA (0.3 mg/kg, i.p.). The second set included three groups, treated with either saline (control), CGS 21680 (0.5 mg/kg, i.p.) or CPA (0.3 mg/kg, i.p.).
Image Analysis
Two types of analysis, at two different levels of magnification, were performed. At the lower magnification level, the total number of c-Fos positive nuclei and the averaged hybridization signal were measured from the areas of the Nucleus Accumbens (NAc) and Caudate-Putamen (CPu) shown in Figure 1 . For quantification of c-Fos immuno- Striatal gene expression and adenosine receptors M Karcz-Kubicha et al reactivity, positive nuclei were counted by using IPLab (version 3.5) software (Scanalytics, Billerica, MA). Phosphoimages were quantified using Image Gauge software (v3.46, Fujifilm, Stamford, CT). Hybridization signal was measured bilaterally for each rat by tracing 4-6 sections and calculating an averaged photo stimulated luminescence (PSL) over the 4-6 sections for each animal group. At the higher magnification level, the number of cell profiles per field (200 Â 200 mm) containing preproenkephalin or preprodynorphin mRNA and c-Fos immunoreactivity was calculated. A neuron was considered double labeled when its nucleus was brown and contained an aggregation of silver particles clearly above the immediately surrounding background. Background was evaluated from slides hybridized with sense probes. Double-labeled cells were counted in a total of 2-3 nonoverlapping fields per four nonadjacent sections per rat (with a separation of at least 100 mm between the sections, to avoid repeated counting of the same cells). Material was analyzed and photographed under bright field (for c-Fos immunoreactivity) or epiluminescence (for mRNA signal) microscopy using a Nikon Eclipse E 800 microscope with 20 Â objective lenses. Images were opened and processed with a Photoshop 5.5 program (Adobe, Seattle, WA). Figure 1 shows a schematic drawing of rat brain section at the level of brain areas analyzed for c-Fos immunohistochemistry and preproenkephalin or preprodynorphin mRNA in situ hybridization. Non-paired Student's t-test was used for statistical analysis. 
-fos Expression in Striatal Enkephalinergic Neurons
The NAc was chosen for the co-localization analysis since the present and previous studies (Karcz-Kubicha et al, 2003) showed that this is the striatal region with the largest increase in c-fos expression after co-administration of adenosine A 2A and A 1 receptor agonists. The simultaneous detection of c-Fos immunoreactivity and preproenkephalin or preprodynorphin transcripts in the NAc showed a significant increase in the number of c-Fos immunoreactive cells that co-express preproenkephalin in animals treated with CGS 21680 (0.5 mg/kg) plus CPA (0.3 mg/kg) when compared with control saline-treated animals (non-paired Student's t-test: po0.001; n ¼ 70 and 32 fields for the groups treated with CGS 21680 plus CPA and saline, respectively). The same analysis showed no significant differences between the animals treated with CGS 21680 plus CPA and controls in the number of c-Fos immunoreactive cells co-expressing preprodynorphin or those lacking preproenkephalin and preprodynorphin expression (Figures 5 and 6 ).
DISCUSSION
In a previous study it was shown that co-administration of the A 1 receptor agonist CPA and the A 2A receptor agonist CGS 21680 increases the expression of the immediate-early gene c-fos in the striatum (Karcz-Kubicha et al, 2003) . In the present study, we demonstrate that this increase is selective for the GABAergic enkephalinergic neurons. Furthermore, A 1 -A 2A receptor co-stimulation induced an increase in the expression of the neuropeptide gene preproenkephalin, but not preprodynorphin. These were expected findings given the fact that GABAergic enkephalinergic neurons show the highest expression of A 2A receptors in the brain (Schiffmann et al, 1991; Hettinger et al, 2001) .
Adenosine A 2A receptors are Gs-olf protein-coupled receptors whose main signaling pathway is adenylyl-cyclase activation, the cAMP-PKA cascade (Kull et al, 1999 (Kull et al, , 2000 . Important PKA substrates include the dopamine and cyclic adenosine 3 0 ,5 0 -monophosphate-regulated phophoprotein, 32 kDa (DARPP-32) and the nuclear constitutive transcription factor cAMP response element binding protein (CREB) (Greengard et al, 1999) . DARPP-32 acts as an amplificatory mechanism of the cAMP-PKA cascade and it has been suggested to be essential for striatal A 2A receptor signaling (Svenningsson et al, 1998; Lindskog et al, 2002) . The catalytic subunits of PKA can diffuse into the nucleus and induce cellular gene expression by phosphorylating CREB. The immediate-early gene c-fos and the preproenkephalin gene are very well-studied target genes the promoters of which contain consensus sites for pCREB binding (Borsook and Hyman, 1995; Herdegen and Leah, 1998) . Thus, A 2A receptor stimulation can potentially activate the cAMP-PKA cascade and increase the expression of immediate-early genes and the preproenkephalin gene, which codes for the precursor of enkephalin.
A 2A and D 2 receptors form heteromeric complexes with reciprocal antagonistic interactions that regulate the function of the GABAergic enkephalinergic neurons (Ferré et al, 1991 (Ferré et al, , 1993 (Ferré et al, , 1997 Agnati et al, 2003; Canals et al, 2003; Kamiya et al, 2003; Ciruela et al, 2004; Woods and Ferré, 2005) . Stimulation of A 2A receptors decreases the affinity of D 2 receptors for agonists by means of an intramembrane interaction (Ferré et al, 1991) , while stimulation of D 2 receptors inhibits A 2A receptor-induced activation of adenylyl-cyclase (Kull et al, 1999; Hillion et al, 2002) . By means of the strong antagonistic D 2 -A 2A receptor interaction at the adenylyl cyclase level, and due to the existence of a tonic effect of dopamine on D 2 receptors, under normal conditions A 2A receptors are practically unable to activate the cAMP-PKA signaling pathway (Agnati et al, 2003; Ferré et al, 2003 Ferré et al, , 2004 . In fact, the systemic administration of A 2A receptor antagonists produces either no effect or a modest decrease in the striatal expression of c-fos or preproenkephalin (Le Moine et al, 1997; Pinna et al, 1997; Aoyama et al, 2002; Carta et al, 2002; Karcz-Kubicha et al, 2003; Wardas et al, 2003) . It must also be pointed out that some studies suggest that A 2A and D 2 receptor can interact synergistically, with stimulation of D 2 receptors potentiating the effects of A 2A receptor stimulation. These conditions seem to depend on the isoform of adenylyl cyclase involved or on the interruption of a previous long-term exposure to D 2 receptor agonists (Yao et al, 2002; Kudlacek et al, 2003; Vortherms and Watts, 2004) . In any case, the main isoform of adenylyl cyclase in the striatum is AC5, and co-stimulation of G s -and G i -coupled receptors shows antagonistic interactions at the AC5 level (Chern, 2000; Defer et al, 2000) . In fact, D 2 receptor stimulation has been shown to counteract cAMP accumulation induced by A 2A receptor stimulation in membrane preparations from mouse striatum (Lee et al, 2002) .
The effects on the striatal expression of c-fos and preproenkephalin observed in the present study depend on the concomitant administration of A 1 and A 2A agonists, since neither agonist produced any effect when administered alone. Nevertheless, in our previous study, the A 1 receptor agonist CPA alone induced a significant increase in c-fos expression in the medial part of the NAc (Karcz -Kubicha et al, 2003) . The simultaneous analysis of the medial and lateral parts of the NAc might have diluted such a local effect of CPA. We have previously suggested that the inability of the A 2A receptor agonist CGS 21680 to induce an increase in the striatal expression of c-fos depends on its ability to produce striatal dopamine release (Karcz-Kubicha et al, 2003) , which further stimulates D 2 receptors and, therefore, antagonizes the effects of A 2A receptor stimulation by the exogenous agonist. CPA administration was shown to decrease the striatal extracellular concentration of dopamine and to counteract CGS 21680-induced dopamine release (Karcz-Kubicha et al, 2003) . Therefore, this local-circuit mechanism can explain why activation of adenosine A 1 receptors allows A 2A receptors to overcome the inhibitory effect of D 2 receptors and induce striatal expression of c-fos and preproenkephalin. We have recently studied the mechanisms involved in the A 2A receptor-mediated striatal dopamine release and suggested that it depends on glutamate neurotransmission (facilitation of glutamate release by the stimulation of A 2A receptor localized in striatal glutamatergic terminals) and NMDA receptor stimulation (facilitation of dopamine release by spillover of glutamate and stimulation of NMDA receptors localized in dopaminergic terminals) (Quarta et al, 2004) . Concomitant administration of an A 1 receptor agonist counteracts CGS 21680-induced dopamine release (Karcz-Kubicha et al, 2003) most probably by indirect inhibitory effects on glutamate release (Quarta et al, 2004) and direct inhibitory effects on dopamine release (Borycz et al, in preparation) . Whatever the mechanisms involved, concomitant A 1 receptor stimulation, which is actually what occurs with endogenous adenosine release, enables A 2A receptor stimulation to produce a significant increase in the striatal expression of c-fos and preproenkephalin.
The present results underscore the role of adenosine in the activation of gene expression in the GABAergic enkephalinergic neuron. Previous studies showed evidence for an opposite modulatory role of adenosine in the other major striatal neuronal element, the GABAergic dynorphinergic neuron, where activation of A 1 receptors attenuates dopamine D 1 receptor-mediated release of GABA and increase in the striatal expression of the immediate-early genes NGFI-A, c-fos and jun-B (Ferré et al, 1996 . Therefore, under physiological conditions of increased adenosine release, a preferential activation of GABAergic enkephalinergic vs GABAergic dynorphinergic neurons must take place. Since this activation has consequences at the gene level, adenosine could selectively facilitate plastic changes in the synapses of the GABAergic enkephalinergic neurons, which can have implications for drug therapy in neuropsychiatric disorders and drug abuse. For instance, there is experimental evidence for the existence of selective gene expression in GABAergic enkephalinergic neurons during sensitization to the behavioral effects of psychostimulants (Uslaner et al, 2001) . In fact, genetic inactivation of A 2A receptors has been reported to attenuate amphetamineinduced behavioral sensitization (Chen et al, 2003) .
